UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`LIQUIDIA TECHNOLOGIES, INC.,
`Petitioner
`
`v.
`
`UNITED THERAPEUTICS CORPORATION,
`Patent Owner
`
`
`
`
`Case No. IPR2021-00406
`U.S. Patent No. 10,716,793
`
`
`
`
`PETITIONER’S UPDATED EXHIBIT LIST
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`LIQUIDIA TECHNOLOGIES, INC.,
`Petitioner
`
`v.
`
`UNITED THERAPEUTICS CORPORATION,
`Patent Owner
`
`
`
`
`Case No. IPR2021-00406
`U.S. Patent No. 10,716,793
`
`
`
`
`PETITIONER’S UPDATED EXHIBIT LIST
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2021-00406
`U.S. Patent No. 10,716,793
`
`
`
`
`Description of Document
`
`Exhibit
`No.
`1001 U.S. Patent No. 10,716,793 B2 to Olschewski, et al. (“’793 patent”)
`1002 Declaration of Dr. Nicholas Hill (“Hill Decl.”)
`1003 Curriculum Vitae of Dr. Nicholas Hill
`1004 Declaration of Dr. Igor Gonda (“Gonda Decl.”)
`1005 Curriculum Vitae of Dr. Igor Gonda
`1006 U.S. Patent No. 6,521,212 B1 to Cloutier, et al. (“’212 patent”)
`1007 Voswinckel, R., et al., Abstract 218: “Inhaled treprostinil is a potent
`pulmonary vasodilator in severe pulmonary hypertension,” European
`Heart Journal 25:22 (2004) (“Voswinckel JESC”)
`1008 Robert Voswinckel, Beate Enke, Andre Kreckel, Frank
`Reichenberger, Stefanie Krick, Henning Gall, Tobias Gessier, Thomas
`Schmehl, Markus G. Kohstall, Friedrich Grimminger, Hossein A.
`Ghofrani, Werner Seeger, and Horst Olschewski, Abstract 1414:
`“Inhaled Treprostinil Sodium (TRE) For the Treatment of Pulmonary
`Hypertension,” Abstracts from the 2004 Scientific Sessions of the
`American Heart Association, Circulation, 110(17 Suppl.):III-295
`(October 26, 2004) (“Voswinckel JAHA”)
`1009 Robert Voswinckel, Hossein A. Ghofrani, Friedrich Grimminger, and
`Werner Seeger, “Clinical Observations” on “Inhaled Treprostinil for
`Treatment of Chronic Pulmonary Arterial Hypertension,” “Letters”
`Section of the Annals of Internal Medicine, 144(2):149-50 (January
`2006) (“Voswinckel 2006”)
`1010 Hossein Ardeschir Ghofrani, Robert Voswinckel, et al., Neue
`Therapieoptionen in der Behandlung der pulmonalarteriellen
`Hypertonie, 30(4) HERZ, 30(4):296–302 (June 2005) (“Ghofrani”)
`(Foreign article and English translation attached)
`First Amended Complaint filed in United Therapeutics Corporation
`v. Liquidia Technologies, Inc., Case No. 1:20-cv-00755-RGA (D.
`Del.)
`
`1011
`
`
`
`1
`
`
`
`IPR2021-00406
`U.S. Patent No. 10,716,793
`
`
`Exhibit
`Description of Document
`No.
`1012 United Therapeutics Corporation’s Answer to Defendant Liquidia
`Technologies, Inc.’s Counterclaims filed in United Therapeutics
`Corporation v. Liquidia Technologies, Inc., Case No. 1:20-cv-00755-
`RGA (D. Del.)
`1013 United Therapeutics Corporation’s Opening Brief in Support of its
`Motion to Dismiss Defendant’s Counterclaim filed in United
`Therapeutics Corporation v. Liquidia Technologies, Inc., Case No.
`1:20-cv-00755-RGA (D. Del.)
`1014 Memorandum Order denying United Therapeutics Corporation’s
`Motion to Dismiss Defendants Counterclaim filed in United
`Therapeutics Corporation v. Liquidia Technologies, Inc., Case No.
`1:20-cv-00755-RGA (D. Del.)
`
`10,716,793 Patent Prosecution History
`
`10,376,525 Patent Prosecution History (excerpted)
`
`1015
`1016
`1017
`9,339,507 Patent Prosecution History (excerpted)
`1018 Remodulin® 2004 Label
`Stein, S.W., et al., “The History of Therapeutic Aerosols: A
`1019
`Chronological Review,” Journal of Aerosol Medicine and
`Pulmonary Drug Delivery, 30(1):20-41 (2017) (“Stein”)
`1020 Clark, A.R., “Medical Aerosol Inhalers: Past, Present, and Future,”
`Aerosol Science and Technology, 22:374-91 (1995) (“Clark”)
`1021 Ruan, C.-H., et al., “Prostacyclin Therapy for Pulmonary Arterial
`Hypertension,” Texas Heart Institute Journal, 37(4):391-99 (2010)
`(“Ruan”)
`1022 Walmrath, D., et al., “Direct Comparison of Inhaled Nitric Oxide and
`Aerosolized Prostacyclin in Acute Respiratory Distress Syndrome,”
`American Journal of Respiratory Critical Care Medicine, 153:991-
`96 (1996) (“Walmrath 1996”)
`
`
`
`2
`
`
`
`IPR2021-00406
`U.S. Patent No. 10,716,793
`
`
`Exhibit
`Description of Document
`No.
`1023 Olschewski, H., et al., “Inhaled Prostacyclin and Iloprost in Severe
`Pulmonary Hypertension Secondary to Lung Fibrosis,” American
`Journal of Respiratory Critical Care Medicine, 160:600-07 (1999)
`(“Olschewski 1999”)
`1024 Haché, M., et al., “Inhaled epoprostenol (prostacyclin) and
`pulmonary hypertension before cardiac surgery,” Journal of
`Thoracic and Cardiovascular Surgery, 125:642-49 (2003) (“Hache”)
`1025 De Wet, C.J., et al., “Inhaled prostacyclin is safe, effective, and
`affordable in patients with pulmonary hypertension, right heart
`dysfunction, and refractory hypoxemia after cardiothoracic surgery,”
`Journal of Thoracic and Cardiovascular Surgery, 127:1058-67
`(2004) (“De Wet”)
`1026 Denver, J. and Dyche, T., “The Adaptive Aerosol Delivery (AAD)
`Technology: Past, Present, and Future,” Journal of Aerosol Medicine
`and Pulmonary Drug Delivery, 23(1 suppl):S-1-S10 (2010) (“Denver
`and Dyche”)
`1027 U.S. Patent No. 6,242,482 B1 to Shorr, et al. (“Shorr”)
`1028 U.S. Patent Application Publication No. US 2004/0265238 A1 to
`Chaudry (“Chaudry”)
`1029 Ventavis® Label 2004
`1030 Newman, S.P., “Aerosols”, Chapter from Encyclopedia of
`Respiratory Medicine pp. 58-64 (2006) (“Newman”)
`1031 Geller, D.E., “Comparing Clinical Features of the Nebulizer,
`Metered-Dose Inhaler, and Dry Powder Inhaler,” Respiratory Care,
`50(10):1313-21 (2005) (“Geller 2005”)
`1032 Bender, B., et al., “Nonadherence in asthmatic patients: is there a
`solution to the problem?” Annals of Allergy, Asthma & Immunology,
`79:177-86 (1997) (“Bender 1997”)
`1033 Rau, J.L., “Determinants of Patient Adherence to an Aerosol
`Regimen,” Respiratory Care 50(10):1346-56 (2005) (“Rau 2005”)
`
`
`
`3
`
`
`
`IPR2021-00406
`U.S. Patent No. 10,716,793
`
`
`Exhibit
`Description of Document
`No.
`1034 Geller, D., et al., “Bolus Inhalation of rhDNase with the AERx
`System in Subjects with Cystic Fibrosis,” Journal of Aerosol
`Medicine, 16(2):175-82 (2003) (“Geller 2003”)
`1035 Chattaraj, S.C., “Treprostinil sodium Pharmacia,” Current Opinion
`in Investigational Drugs, 3(4):582-86 (Apr. 2002), available at
`https://pubmed.ncbi.nlm.nih.gov/12090728/ (“Chattaraj”)
`1036 Declaration of Sylvia Hall-Ellis, Ph.D. (“Hall-Ellis Decl.”)
`1037
`English translation of OptiNeb® User Manual 2005
`1038 Atkins, P.J., “Dry Powder Inhalers: An Overview,” Respiratory
`Care, 50(10):1304-12 (2005) (“Atkins”)
`Frijlink, H.W. and De Boer, A.H., “Dry powder inhalers for
`pulmonary drug delivery,” Expert Opinion on Drug Delivery,
`1(1):67-86 (2004) (“Frijlink and De Boer”)
`1040 Chew N. and Chan H.-K., “Pharmaceutical Dry Powder Aerosol
`Delivery,” KONA, No. 19, pp. 46-56 (2001) (Chew and Chan)
`
`1039
`
`1041
`1042
`
`1043
`
`Reserved
`January 27, 2020 Press Release, “Liquidia Submits New Drug
`Application for LIQ861 (Treprostinil) Inhalation Powder to U.S.
`Food And Drug Administration for the Treatment of Pulmonary
`Arterial Hypertension (PAH),” available at
`https://investors.liquidia.com/news-releases/news-release-
`details/liquidia-submits-new-drug-application-liq861-treprostinil
`2009 Tyvaso® Label, available at
`https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022387s
`015lbl.pdf
`
`9,358,240 Patent Prosecution History (excerpted)
`
`1044
`1045
`Reserved
`1046 U.S. Patent No. 9,358,240 to Olschewski, et al. (“’240 Patent”)
`
`
`
`4
`
`
`
`IPR2021-00406
`U.S. Patent No. 10,716,793
`
`
`Exhibit
`Description of Document
`No.
`1047 Hoeper, M.M., et al., “Long-Term Treatment of Primary Pulmonary
`Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue,” N
`Engl J Med, 342:1866-70 (2000) (“Hoeper”)
`1048 Walmrath, D., et al., “Aerosolised prostacyclin in adult respiratory
`distress syndrome,” Lancet, 342:961-62 (1993) (“Walmrath 1993”)
`1049 April 8, 2020 Press Release, “Liquidia Announces FDA Acceptance
`of New Drug Application for LIQ861 (Treprostinil) Inhalation
`Powder for the Treatment of Pulmonary Arterial Hypertension,”
`available at https://investors.liquidia.com/news-releases/news-
`release-details/liquidia-announces-fda-acceptance-new-drug-
`application-liq861
`
`1050
`1051
`
`Pulmozyme® Label
`Farber, H.W. and Loscalzo, J., “Pulmonary Arterial Hypertension,”
`N Engl J Med, 351:1655-65 (2004) (“Farber and Loscalzo”)
`1052 Rubin, L.J. and Badesch, D.B., “Evaluation and Management of the
`Patient with Pulmonary Arterial Hypertension,” Ann Intern Med.,
`143:282-92 (2005) (“Rubin and Badesch”)
`
`1053
`Flolan® Label
`1054 Gonda, I., “A semi-empirical model of aerosol deposition in the
`human respiratory tract for mouth inhalation,” J. Pharm.
`Pharmacol., 33:692-96 (1981) (“Gonda 1981”)
`1055 Gonda, I., “Study of the effects of polydispersity of aerosols on
`regional deposition in the respiratory tract,” J. Pharm. Pharmacol.,
`33 (Suppl.) 52P (1981) (“Gonda 1981b”)
`Telko, M.J. and Hickey, A.J., “Dry Powder Inhaler Formulation,”
`Respiratory Care, 50(9):1209-27 (2005) (“Telko and Hickey”)
`1057 October 24, 2005 Press Release, “Aradigm Corporation And United
`Therapeutics Corporation Sign Development and Commercialization
`Agreement Targeting Pulmonary Hypertension,” available at
`https://www.biospace.com/article/releases/aradigm-corporation-and-
`united-therapeutics-corporation-sign-development-and-
`
`1056
`
`
`
`5
`
`
`
`IPR2021-00406
`U.S. Patent No. 10,716,793
`
`
`Exhibit
`No.
`
`1058
`
`Description of Document
`commercialization-agreement-targeting-pulmonary-hypertension-/
`Ziegler, J. and Wachtel, H., “Comparison of Cascade Impaction and
`Laser Diffraction for Particle Size Distribution Measurements,”
`Journal of Aerosol Medicine, 18(3):311-24 (2005) (“Ziegler and
`Wachtel”)
`1059 Nauser, T.D., “Pulmonary Hypertension: New Perspectives,” CHF,
`9:155-62 (2003) (“Nauser 2003”)
`Pitcairn, G., et al., “Deposition of Corticosteroid Aerosol in the
`Human Lung by Respimat® Soft Mist™ Inhaler Compared to
`Deposition by Metered Dose Inhaler or by Turbuhaler® Dry Powder
`Inhaler,” Journal of Aerosol Medicine, 18(3):264-72 (2005)
`(“Pitcairn”)
`1061 Dalby, R., et al., “A review of the development of Respimat® Soft
`MistTM Inhaler,” International Journal of Pharmaceutics, 283:1-9
`(2004) (“Dalby”)
`1062 Gessler, T., et al., “Ultrasonic versus jet nebulization of iloprost in
`severe pulmonary hypertension,” Eur Respir J, 17:14-19 (2001)
`(“Gessler”)
`
`1060
`
`1063
`Reserved
`1064 Dolovich, M.B., et al., “Device Selection and Outcomes of Aerosol
`Therapy: Evidence-Based Guidelines,” CHEST, 127:335-71 (2005)
`(“Dolovich”)
`1065 Olschewski, H., et al., “Inhaled Iloprost for Several Pulmonary
`Hypertension,” N Engl J Med, 347(5):322-29 (2002) (“Olschewski
`2002”)
`1066 AccuNeb® Label
`1067 Anderson, P.J., “History of Aerosol Therapy: Liquid Nebulization to
`MDIs to DPIs,” Respiratory Care, 50(9):1139-49 (2005) (“Anderson
`2005”)
`
`
`
`6
`
`
`
`IPR2021-00406
`U.S. Patent No. 10,716,793
`
`
`1069
`
`Exhibit
`Description of Document
`No.
`1068 Vachiéry, J.-L., et al., “Transitioning From IV Epoprostenol to
`Subcutaneous Treprostinil in Pulmonary Arterial Hypertension,”
`CHEST, 121:1561-65 (2002) (“Vachiéry 2002”)
`Zierenberg, B. and Eicher, J., Chapter 78 “The Respimat, a New Soft
`Mist Inahler for Delivering Drugs to The Lungs,” MODIFIED-
`RELEASE DRUG DELIVERY TECHNOLOGY (2002) pp.925-933
`(“Zierenberg”)
`1070 Beasley, R., et al., “Preservatives in Nebulizer Solutions: Risks
`without Benefit,” Pharmacotherapy, 18(1):130-39 (1998)
`(“Beasley”)
`Prober, C.G., et al., “Technical Report: Precautions Regarding the
`Use of Aerosolized Antibiotics,” Pediatrics, 106(6):1-6 (2000)
`(“Prober”)
`
`1071
`
`1072
`Reserved
`1073 Aradigm Corporation Form 10-Q for the quarterly period ended June
`30, 2009, available at
`https://www.sec.gov/Archives/edgar/data/1013238/00009501230903
`1361/f53244e10vq.htm
`1074 Orenitram® Label, available at
`https://www.orenitram.com/pdf/Orenitram-Prescribing-
`Information.pdf
`1075 November 17, 2008 Press Release, “Eli Lilly and Company Licenses
`U.S. Rights for Tadalafil PAH Indication to United Therapeutics
`Corporation,” available at
`https://www.fiercebiotech.com/biotech/eli-lilly-and-company-
`licenses-u-s-rights-for-tadalafil-pah-indication-to-united
`1076 October 23, 2017 Press Release, “United Therapeutics Announces
`FDA Approval Of Third Generation Nebulizer For The Tyvaso®
`Inhalation System,” available at https://www.prnewswire.com/news-
`releases/united-therapeutics-announces-fda-approval-of-third-
`generation-nebulizer-for-the-tyvaso-inhalation-system-
`300540953.html
`
`
`
`7
`
`
`
`IPR2021-00406
`U.S. Patent No. 10,716,793
`
`
`Exhibit
`Description of Document
`No.
`1077 Boyle, M.P., “So Many Drugs, So Little Time. The Future Challenge
`of Cystic Fibrosis Care,” CHEST, 123(1):3-5 (2003) (“Boyle 2003”)
`1078 Azmacort® Label 2003
`1079 Hill, N.S., et al., “Inhaled Therapies for Pulmonary Hypertension,”
`Respiratory Care, 60(6):794-805 (2015) (“Hill 2015”)
`1080 Declaration of Deepa Kannappan in Support of Motion for Pro Hac
`Vice Admission
`1081 Biography of Deepa Kannappan
`1082 Biography of Jonathan Davies
`1083 Declaration of Jonathan Davies in Support of Motion for Pro Hace
`Vice Admission
`1084
`Reserved
`1085
`Reserved
`1086
`Reserved
`1087 Butler Affidavit
`1088
`Tyvaso® Label 2021 (Note: PO’s Ex. 2034, described as “Tyvaso®
`Label 2021,” is the 2009 label)
`1089 Voswinckel JESC, UWash
`1090 Voswinckel JESC, UWisc
`1091 Voswinckel JESC, British Library
`1092 Voswinckel JESC, Additional Pages
`1093 Voswinckel JAHA, British Library
`1094 Voswinckel JAHA, Library of Congress
`1095 Voswinckel JAHA, Stanford
`1096 Voswinckel JAHA, UC Davis
`
`
`
`8
`
`
`
`IPR2021-00406
`U.S. Patent No. 10,716,793
`
`
`Description of Document
`
`Exhibit
`No.
`1097 Rhind, G.B. et al., “Effect of Spirometry of Distilled Water and
`Cromoglycate Solutions Nebulised by a Small Portable Ultrasonic
`Nebuliser,” Respiration, 51:86-90 (1987) (“Rhind 1987”)
`1098 Hager, J., et al., “Measurement of Particle and Mass Distribution of
`Pentamidine Aerosol by Ultrasonic and Air Jet Nebulizers,” Journal
`of Aerosol Medicine, Vol. 5, No. 2 (1992) (“Hager 1992”)
`Leigh, T.R., et al., “Performance characteristics of the DeVilbiss
`Ultraneb 99 ultrasonic nebuliser with reference to use in sputum
`induction,” International Journal of Pharmaceutics, 67 (1991) 275-
`282 (“Leigh 1991”)
`1100 Ventavis EU Summary of Product Characteristics
`1101 Denyer, J., et al., “Adaptive Aerosol Delivery (AAD®) technology,”
`Expert Opinion on Drug Delivery, 1:1, 165-176 (“Denyer 2004”)
`1102 Byrne, N.M., et al., “Comparison of lung deposition of colomycin
`using the HaloLite and the Pari LC Plus nebulisers in patients with
`cystic fibrosis,” Arch Dis Child 2003;88:715–718 (“Byrne 2003”)
`Leung, K., et al., “Comparison of Breath-Enhanced to Breath-
`Actuated Nebulizers for Rate, Consistency, and Efficiency,” CHEST
`2004; 126:1619–1627 (“Leung 2004”)
`Sulica, R. and Poon, M., “Medical therapeutics for pulmonary
`arterial hypertension: from basic science and clinical trial design to
`evidence-based medicine,” Expert Rev. Cardiovasc. Ther. 3(2),
`(2005) (“Sulica 2005”)
`1105
`European Society of Cardiology Annual Report 2005
`1106 Reply Declaration of Nicholas Hill, M.D.
`1107 Reply Declaration of Igor Gonda, Ph.D.
`1108
`Transcript from the January 8, 2022 Deposition of Aaron Waxman,
`M.D., Ph.D., Liquida Technologies, Inc. v. United Therapeutics
`Corp., IPR2021-00406
`Transcript from the January 11, 2022 Deposition of Jason
`McConville, Liquida Technologies, Inc. v. United Therapeutics
`Corp., IPR2021-00406
`
`1099
`
`1103
`
`1104
`
`1109
`
`
`
`9
`
`
`
`IPR2021-00406
`U.S. Patent No. 10,716,793
`
`
`Exhibit
`No.
`1110
`
`Description of Document
`
`Transcript from the December 29, 2021 Deposition of Lyndsey Pilar
`Wyman, Liquida Technologies, Inc. v. United Therapeutics Corp.,
`IPR2021-00406
`1111
`Reserved
`1112 Reply Declaration of Sylvia Hall-Ellis, Ph.D.
`1113 Voswinckel JAHA Supplemental Author Index
`1114 American Heart Association 2004 Online Archive, pages available
`at
`https://web.archive.org/web/20041130084648/http://circ.ahajournals.
`org:80/;
`https://web.archive.org/web/20041206215947/http://aha.agora.com/a
`bstractviewer/;
`https://web.archive.org/web/20041128050933/http://circ.ahajournals.
`org/contents-by-date.0.shtml; and
`https://web.archive.org/web/20041204145419/http://circ.ahajournals.
`org/content/vol110/issue17/
`1115 Affidavit of Duncan Hall, December 7, 2021
`1116 Voswinckel JAHA British Library Declaration
`1117 Voswinckel JAHA Supplement PubMed Search Results
`1118
`PubMed.gov search results for Sulica, R. and Poon, M., “Medical
`therapeutics for pulmonary arterial hypertension: from basic science
`and clinical trial design to evidence-based medicine,” Expert Rev.
`Cardiovasc. Ther. 3(2), (2005)
`1119 Voswinckel JESC British Library Declaration
`1120 Voswinckel JESC Web of Science Search Results
`1121 Ghofrani 2005, British Library
`1122 Ghofrani 2005 Search Results
`1123 Circulation MARC record, British Library
`1124 Circulation MARC record, Library of Congress
`1125 Circulation MARC record, Stanford
`
`
`
`10
`
`
`
`IPR2021-00406
`U.S. Patent No. 10,716,793
`
`
`Description of Document
`
`Exhibit
`No.
`1126 Circulation MARC record, UC Davis
`1127
`European Heart Journal bibliographic record, UWash
`1128
`European Heart Journal MARC record, UWisc
`1129
`European Heart Journal MARC record, British Library
`1130
`January 27, 2020 Press Release “Liquidia Submits New Drug
`Application for LIQ861 (treprostinil) inhalation powder to U.S. Food
`and Drug Administration for the Treatment of Pulmonary Arterial
`Hypertension (PAH),” available at https://www.liquidia.com/news-
`releases/news-release-details/liquidia-submits-new-drug-application-
`liq861-treprostinil
`1131 Michael Mellon et al., Comparable Efficacy of Administration with
`Face Mask or Mouthpiece of Nebulized Budesonide Inhalation
`Suspension for Infants and Young Children with Persistent Asthma,
`162 AM. J. RESPIR. CARE MED. 593 (2000) (“Mellon 2000”)
`Transcript from the January 15, 2022 deposition of Aaron B.
`Waxman, M.D., Ph.D., United Therapeutics Corp. v. Liquidia
`Technologies, Inc., Case No. 1:20-cv-00755 (D. Del.) (excerpted)
`
`1132
`
`
`
`
`Dated: February 10, 2022
`
`COOLEY LLP
`ATTN: Patent Group
`1299 Pennsylvania Avenue NW
`Suite 700
`Washington, D.C. 20004
`Tel: (212) 479-6840
`Fax: (212) 479-6275
`
`
`
`
`
`
`
`
`By:
`
`
`
`
`Respectfully submitted,
`
`
`/Ivor R. Elrifi/
`Ivor R. Elrifi
`Reg. No. 39,529
`Counsel for Petitioner
`
`
`
`11
`
`
`
`IPR2021-00406
`U.S. Patent No. 10,716,793
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. §§42.6(e)(4)(i) et seq., a complete copy of the attached
`PETITIONER’S UPDATED EXHIBIT LIST and related documents are being
`served via email on the 10th day of February 2022, upon Patent Owner’s attorneys
`of record:
`
`Stephen B. Maebius (smaebius@foley.com)
`UT-793@foley.com
`UTCvLiquidia-IPR@mwe.com
`
`
`
`
`
`By:
`
`
`
`
`
`/Ivor R. Elrifi/
`Ivor R. Elrifi
`Reg. No. 39,529
`Counsel for Petitioner
`
`
`
`Dated: February 10, 2022
`
`COOLEY LLP
`ATTN: Patent Group
`1299 Pennsylvania Avenue NW
`Suite 700
`Washington, D.C. 20004
`Tel: (212) 479-6840
`Fax: (212) 479-6275
`
`
`
`
`
`
`
`
`12
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
